Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $75.8 million.

  • Cidara Therapeutics' Non-Current Assets rose 1263.83% to $75.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.8 million, marking a year-over-year increase of 1263.83%. This contributed to the annual value of $4.1 million for FY2024, which is 34.27% down from last year.
  • As of Q3 2025, Cidara Therapeutics' Non-Current Assets stood at $75.8 million, which was up 2,890.10% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Non-Current Assets ranged from a high of $75.8 million in Q3 2025 and a low of $2.2 million during Q1 2023.
  • Moreover, its 3-year median value for Non-Current Assets was $5.6 million (2024), whereas its average is $11.0 million.
  • The largest annual percentage gain for Cidara Therapeutics' Non-Current Assets in the last 5 years was 1,263.83% (2025), contrasted with its biggest fall of 51.05% (2025).
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Non-Current Assets stood at $3.6 million in 2021, then tumbled by 34.02% to $2.4 million in 2022, then surged by 158.04% to $6.2 million in 2023, then crashed by 34.27% to $4.1 million in 2024, then soared by 1,263.83% to $75.8 million in 2025.
  • Its Non-Current Assets was $75.8 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.9 million in Q1 2025.